Identification of JTP-70902, a P15(INK4b)-inductive Compound, As a Novel MEK1/2 Inhibitor

Overview

Journal Cancer Sci

Specialty Oncology

Date 2007 Sep 6

PMID 17784872

Citations 22

Authors

Takayuki Yamaguchi

Takayuki Yoshida

Reina Kurachi

Junya Kakegawa

Yoshikazu Hori

Toyomichi Nanayama

Kazuhide Hayakawa

Hiroyuki Abe

Koichi Takagi

Youichirou Matsuzaki

Makoto Koyama

Shingo Yogosawa

Yoshihiro Sowa

Takao Yamori

Nobuyuki Tajima

Toshiyuki Sakai

Affiliations

Soon will be listed here.

Abstract

The INK4 family members p16(INK4a) and p15(INK4b) negatively regulate cell cycle progression by inhibition of cyclin-dependent kinase (CDK) 4/6. Loss of p16(INK4a) functional activity is frequently observed in tumor cells, and is thought to be one of the primary causes of carcinogenesis. In contrast, despite the biochemical similarity to p16(INK4a), the frequency of defects in p15(INK4b) was found to be lower than in p16(INK4a), suggesting that p15(INK4b)-inductive agents may be useful for tumor suppression. Here we report the discovery of a novel pyrido-pyrimidine derivative, JTP-70902, which exhibits p15(INK4b)-inducing activity in p16(INK4a)-inactivated human colon cancer HT-29 cells. JTP-70902 also induced another CDK-inhibitor, p27(KIP1), and downregulated the expression of c-Myc and cyclin D1, resulting in G(1) cell cycle arrest. MEK1/2 was identified by compound-immobilized affinity chromatography as the molecular target of JTP-70902, and this was further confirmed by the inhibitory activity of JTP-70902 against MEK1/2 in kinase assays. JTP-70902 suppressed the growth of most colorectal and some other cancer cell lines in vitro, and showed antitumor activity in an HT-29 xenograft model. However, JTP-70902 did not inhibit the growth of COLO320 DM cells; in these, constitutive extracellular signal-regulated kinase phosphorylation was not detected, and neither p15(INK4b) nor p27(KIP1) induction was observed. Moreover, p15(INK4b)-deficient mouse embryonic fibroblasts were found to be more resistant to the growth-inhibitory effect of JTP-70902 than wild-type mouse embryonic fibroblasts. These findings suggest that JTP-70902 restores CDK inhibitor-mediated cell cycle control by inhibiting MEK1/2 and exerts a potent antitumor effect.

Citing Articles

AI-powered genomic mutation signature for predicting immune checkpoint inhibitor therapy outcomes in gastroesophageal cancer: a multi-cohort analysis.

Yang B, Cheng C, Zhou J, Ni H, Liu H, Fu Y Discov Oncol. 2024; 15(1):507.

PMID: 39342515 PMC: 11439860. DOI: 10.1007/s12672-024-01400-7.

Trametinib activates endogenous neurogenesis and recovers neuropathology in a model of Alzheimer's disease.

Kim M, Kim M, Lee C, Lee J, Kim S, Hong S Exp Mol Med. 2023; 55(10):2177-2189.

PMID: 37779138 PMC: 10618442. DOI: 10.1038/s12276-023-01073-2.

Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction.

Voon P, Chen E, Chen H, Lockhart A, Sahebjam S, Kelly K J Exp Clin Cancer Res. 2022; 41(1):51.

PMID: 35130943 PMC: 8819907. DOI: 10.1186/s13046-021-02236-7.

Kinase Inhibition as Treatment for Acute and Chronic Graft--Host Disease.

Braun L, Zeiser R Front Immunol. 2021; 12:760199.

PMID: 34868001 PMC: 8635802. DOI: 10.3389/fimmu.2021.760199.

Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in Mutant Rhabdomyosarcoma.

Garcia N, Pozo V, Yohe M, Goodwin C, Shackleford T, Wang L Mol Cancer Ther. 2021; 21(1):170-183.

PMID: 34737198 PMC: 8742779. DOI: 10.1158/1535-7163.MCT-21-0194.

References

Sebolt-Leopold J, Herrera R . Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004; 4(12):937-47. DOI: 10.1038/nrc1503. View

Ruas M, Peters G . The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta. 1998; 1378(2):F115-77. DOI: 10.1016/s0304-419x(98)00017-1. View

Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H . Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol. 2001; 3(4):392-9. DOI: 10.1038/35070076. View

Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho R . Role of the INK4a locus in tumor suppression and cell mortality. Cell. 1996; 85(1):27-37. DOI: 10.1016/s0092-8674(00)81079-x. View

Ikehara N, Semba S, Sakashita M, Aoyama N, Kasuga M, Yokozaki H . BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms. Int J Cancer. 2005; 115(6):943-50. DOI: 10.1002/ijc.20957. View

Mallon R, Feldberg L, Kim S, Collins K, Wojciechowicz D, Hollander I . An enzyme-linked immunosorbent assay for the Raf/MEK1/MAPK signaling cascade. Anal Biochem. 2001; 294(1):48-54. DOI: 10.1006/abio.2001.5151. View

Roovers K, Assoian R . Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays. 2000; 22(9):818-26. DOI: 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.0.CO;2-6. View

Yang W, Shen J, Wu M, Arsura M, Fitzgerald M, Suldan Z . Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene. 2001; 20(14):1688-702. DOI: 10.1038/sj.onc.1204245. View

Paull K, Shoemaker R, Hodes L, Monks A, Scudiero D, Rubinstein L . Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst. 1989; 81(14):1088-92. DOI: 10.1093/jnci/81.14.1088. View

10.

Seoane J, Pouponnot C, Staller P, Schader M, Eilers M, Massague J . TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nat Cell Biol. 2001; 3(4):400-8. DOI: 10.1038/35070086. View

11.

Tetsu O, McCormick F . Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell. 2003; 3(3):233-45. DOI: 10.1016/s1535-6108(03)00053-9. View

12.

Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins J . Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000; 14(19):2501-14. PMC: 316970. DOI: 10.1101/gad.836800. View

13.

Solit D, Garraway L, Pratilas C, Sawai A, Getz G, Basso A . BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2005; 439(7074):358-62. PMC: 3306236. DOI: 10.1038/nature04304. View

14.

Fang J, Lu J, Chen Y, Yang L . Effects of DNA methylation on expression of tumor suppressor genes and proto-oncogene in human colon cancer cell lines. World J Gastroenterol. 2003; 9(9):1976-80. PMC: 4656656. DOI: 10.3748/wjg.v9.i9.1976. View

15.

Kubo A, Nakagawa K, Varma R, Conrad N, Cheng J, Lee W . The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clin Cancer Res. 2000; 5(12):4279-86. View

16.

Thullberg M, Bartkova J, Khan S, Hansen K, Ronnstrand L, Lukas J . Distinct versus redundant properties among members of the INK4 family of cyclin-dependent kinase inhibitors. FEBS Lett. 2000; 470(2):161-6. DOI: 10.1016/s0014-5793(00)01307-7. View

17.

Gysin S, Lee S, Dean N, McMahon M . Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. Cancer Res. 2005; 65(11):4870-80. DOI: 10.1158/0008-5472.CAN-04-2848. View

18.

Hiramoto M, Shimizu N, Sugimoto K, Tang J, Kawakami Y, Ito M . Nuclear targeted suppression of NF-kappa B activity by the novel quinone derivative E3330. J Immunol. 1998; 160(2):810-9. View

19.

Wang Z, Li Y, Liu E, Yu Q . Susceptibility to cell death induced by blockade of MAPK pathway in human colorectal cancer cells carrying Ras mutations is dependent on p53 status. Biochem Biophys Res Commun. 2004; 322(2):609-13. DOI: 10.1016/j.bbrc.2004.07.166. View

20.

Mercer K, Pritchard C . Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta. 2003; 1653(1):25-40. DOI: 10.1016/s0304-419x(03)00016-7. View